Nuveen
FBRX

Nuveen’s Forte Biosciences FBRX Stock Holding History

Nuveen’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
+108,347
New +$2.57M ﹤0.01% 2507
2022
Q2 		– Sell
-1,614
Closed -$1.15M – 3331
2022
Q1 		$1.15M Hold
1,614
– – ﹤0.01% 2762
2021
Q4 		$1.15M Sell
1,614
-280
-15% -$18.8K ﹤0.01% 2810
2021
Q3 		$1.35M Buy
1,894
+144
+8% +$79.8K ﹤0.01% 2854
2021
Q2 		$1.47M Buy
+1,750
New +$1.58M ﹤0.01% 2844
2020
Q2 		– Sell
-110
Closed -$50K – 3303
2020
Q1 		$50K Buy
+110
New +$43K ﹤0.01% 3105
2019
Q4 		– Sell
-323
Closed -$80K – 3251
2019
Q3 		$80K Buy
323
+65
+25% +$98.7K ﹤0.01% 3179
2019
Q2 		$646K Buy
+258
New +$765K ﹤0.01% 2918

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Nuveen's FBRX Position: Q2 2026 in Review

Nuveen opened a new position in Forte Biosciences (FBRX) in Q2 2026: 108,347 shares worth $2.3M. The stake represents ﹤0.01% of the portfolio and ranks #2507 among its holdings. This is a return to the name: Nuveen previously reported a position in FBRX as recently as Q1 2022.

Nuveen first reported a position in FBRX in Q2 2019 and has held it in 8 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Nuveen held 108,347 shares of Forte Biosciences worth $2.3M as of Q2 2026.
  • Forte Biosciences was a new Nuveen position in Q2 2026.
  • Forte Biosciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2507 holding.
  • Nuveen first reported a position in Forte Biosciences in Q2 2019 and has held it in 8 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.